Abstract:Abstract Background Transgelin-2 is a 22 kDa actin-binding protein that has been proposed to act as an oncogenic factor, capable of contributing to tumorigenesis in a wide range of human malignancies. However, little is known whether this tiny protein also plays an important role in immunity, thereby keeping body from the cancer development and metastasis. Here, we investigated the functions of transgelin-2 in dendritic cell (DC) immunity. Further, we investigated whether the non-viral transduction of cell-permeable transgelin-2 peptide potentially enhance DC-based cancer immunotherapy. Methods To understand the functions of transgelin-2 in DCs, we utilized bone marrow-derived DCs (BMDCs) purified from transgelin-2 knockout ( Tagln2 −/− ) mice. To observe the dynamic cellular mechanism of transgelin-2, we utilized confocal microscopy and flow cytometry. To monitor DC migration and cognate T–DC interaction in vivo, we used intravital two-photon microscopy. For the solid and metastasis tumor models, OVA + B16F10 melanoma were inoculated into the C57BL/6 mice via intravenously (i.v.) and subcutaneously (s.c.), respectively. OTI TCR T cells were used for the adoptive transfer experiments. Cell-permeable, de-ubiquitinated recombinant transgelin-2 was purified from Escherichia coli and applied for DC-based adoptive immunotherapy. Results We found that transgelin-2 is remarkably expressed in BMDCs during maturation and lipopolysaccharide activation, suggesting that this protein plays a role in DC-based immunity. Although Tagln2 −/− BMDCs exhibited no changes in maturation, they showed significant defects in their abilities to home to draining lymph nodes (LNs) and prime T cells to produce antigen-specific T cell clones, and these changes were associated with a failure to suppress tumor growth and metastasis of OVA + B16F10 melanoma cells in mice. Tagln2 −/− BMDCs had defects in filopodia-like membrane protrusion and podosome formation due to the attenuation of the signals that modulate actin remodeling in vitro and formed short, unstable contacts with cognate CD4 + T cells in vivo. Strikingly, non-viral transduction of cell-permeable, de-ubiquitinated recombinant transgelin-2 potentiated DC functions to suppress tumor growth and metastasis. Conclusion This work demonstrates that transgelin-2 is an essential protein for both cancer and immunity. Therefore, transgelin-2 can act as a double-edged sword depending on how we apply this protein to cancer therapy. Engineering and clinical application of this protein may unveil a new era in DC-based cancer immunotherapy. Our findings indicate that cell-permeable transgelin-2 have a potential clinical value as a cancer immunotherapy based on DCs.

Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer.

Transgelin 2 Overexpression Inhibits Cervical Cancer Cell Invasion and Migration.

Regulation of BMP2K in AP2M1-mediated EGFR Internalization During the Development of Gallbladder Cancer

Identification Of Transgelin-2 As A Biomarker Of Colorectal Cancer By Laser Capture Microdissection And Quantitative Proteome Analysis

TAGLN2 Promotes the Proliferation, Migration, Invasion, and EMT of Clear Cell Renal Cell Carcinoma Through the PI3K/Akt Signaling Pathway

An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer

TGF-β-induced Transgelin Promotes Bladder Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition and Invadopodia Formation

Transgelin 2 guards T cell lipid metabolism and antitumour function

N‐glycan signatures identified in the serum from biliary tract cancer patients: Association with clinical diagnosis and prognosis

Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function

TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway

Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy

Transgelins: Cytoskeletal Associated Proteins Implicated in the Metastasis of Colorectal Cancer

EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance

Genomic feature and potential therapeutic target for cholangiocarcinoma

Downregulation of Transgelin 2 Promotes Breast Cancer Metastasis by Activating the Reactive Oxygen Species/nuclear Factor‑κb Signaling Pathway.

Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma

Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding

M2-like tumor-associated macrophage-secreted CCL2 facilitates gallbladder cancer stemness and metastasis

[Expression of Transgelin-2 and Clinical Significance in Colorectal Cancer].